Abstract
HAP/VAP: Simpler May Be Cetter
Highlights
If we compare and contrast the treatment section of these guidelines with those from the American Thoracic Society – Infectious Diseases Society of America (ATS/IDSA), it becomes immediately obvious that they are quite different (1)
The main determinant in the American approach is whether the patient has risk factors for multidrug-resistant organisms
Most clinicians and investigators would agree that infection with P aeruginosa is more likely to result in a severe clinical presentation than is infection caused by other pathogens
Summary
If we compare and contrast the treatment section of these guidelines with those from the American Thoracic Society – Infectious Diseases Society of America (ATS/IDSA), it becomes immediately obvious that they are quite different (1). The American approach to HAP/VAP certainly has its shortcomings, and there is nothing wrong with disagreeing with this approach as long as the data are there to support such a stance. The main determinant in the American approach is whether the patient has risk factors for multidrug-resistant organisms.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
